Scientists from the Institute of Science of Tokyo have developed a MRNA vaccine that can prevent the loss of vision due to age-yellow stain degeneration (DBD). The results of the study were published in the journal Vaccines.
DBD is one of the main causes of vision loss, which affects almost 200 million people around the world. This chronic disease affects the central part of the retina (DBD), which is responsible for simple and detailed vision.
The new vaccine operates, suppressing neuascularism, the abnormal growth of blood vessels in the retina, which leads to a gradual loss of fluid accumulation and vision. Regular injections of anti-Azerbaijani drugs are currently used to slow down this process. However, such procedures require frequent repetition and are not always effective in the long run.
The vaccine developed by Japanese scientists is based on MRNA encoding LRG1 protein. This protein is connected with the development of abnormal blood vessels in the case of DBD. After the interface injection, the body begins to produce antibodies against this protein, which block the growth of abnormal vessels without affecting healthy tissue.
During the tests on two groups of mice, two injections of the drug were significantly reduced the level of retinal damage to 85%, in the indicated IMA model and up to 55%, in a natural model. The first positive results were viewed within a week after the first dose.
Scientists say the vaccine has shown high security. It has not caused side effects and does not disrupt the retinal blood flow.
"If the effectiveness of this new vaccine is confirmed in clinical trials, it will pass the way to the MCA's more convenient and less traumatic injection instead of ordinary eye injections," said Sautoshi Uchid.
Translation of: Euromedia24.com
